<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE GlossaryTerm >
<GlossaryTerm id="CDR0000543121"><TermName>anti-CD19 immunotoxin</TermName><TermPronunciation>(AN-tee … IH-myoo-noh-TOK-sin)</TermPronunciation><TermDefinition><DefinitionText>A monoclonal antibody linked to a toxic substance. It is being studied in the treatment of some types of B-cell cancer. Anti-CD19 immunotoxin is made in the laboratory. It binds to CD19, a protein on the surface of normal B cells and B-cell tumors, and kills the cells.</DefinitionText><Dictionary>Cancer.gov</Dictionary><Audience>Patient</Audience></TermDefinition><MediaLink ref="CDR0000718162" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;anti-CD19 immunotoxin&quot;" language="en" id="_3"/><MediaLink ref="CDR0000718163" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;inmunotoxina anti-CD19&quot;" language="es" id="_4"/><SpanishTermName>inmunotoxina anti-CD19</SpanishTermName><SpanishTermDefinition><DefinitionText>Anticuerpo monoclonal unido a una sustancia tóxica. Está en estudio para el tratamiento de algunos tipos de cáncer de células B. La inmunotoxina anti-CD19 se produce en el laboratorio. Se une a la CD19, una proteína de la superficie de las células B normales y de las células B tumorales, y destruye las células.</DefinitionText><Dictionary>Cancer.gov</Dictionary><Audience>Patient</Audience></SpanishTermDefinition><DateFirstPublished>2007-08-20</DateFirstPublished></GlossaryTerm>
